CURA Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Curaleaf Holdings (TSE: CURA)
›
Curaleaf Holdings (TSE: CURA) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5,554 employees.
The shares were at 10.94 CAD on 19 November 2026, up 33.6% over 52 weeks. Its 52-week range is 7.770 CAD to 20.92 CAD: the price is 47.7% below the high and 40.8% above the low.
Its market capitalisation is 2.90B CAD.
Curaleaf Holdings reports return on equity of -36.1%, an operating margin of 0.8% and revenue up 10.9% year over year.
Its debt exceeds its cash by 1.04B USD, a debt-to-equity ratio of 1.09. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 19.88 CAD is 81.7% above the current price. The next earnings report is expected on 25 February 2027.